Meridia Insight Medicine Breakthroughs Health

Health care is getting more precise—and more human

From depression and pain to cancer risk and dental care, new research is making treatment more precise—and attentive to the person.

A cream with no active ingredient—and a sense of ownership—may help people tolerate pain longer.

A hand rests in cold water while a participant waits for pain. Across the world, researchers are asking a surprisingly broad question: what else, beyond a drug or procedure, can help people feel better—and how can treatment fit more closely to the person receiving it?

Eight studies offer a hopeful, careful answer. Progress is arriving through better-targeted medicines, smarter combinations of existing care, and tools that may make treatment more personal or accessible. Most findings are early or specific to the populations studied. Together, though, they show health research widening its lens.

The treatment—and the person

For people with treatment-resistant depression, relief can mean more than a change in mood. Anhedonia—the loss of interest or ability to feel pleasure—can make ordinary activities and connection feel distant. In the first randomized, placebo-controlled trial specifically examining psilocybin’s effects on anhedonia in this group, University of Colorado Anschutz researchers found significant improvement eight weeks after treatment among participants who received 25 milligrams. The study, published in the Journal of Affective Disorders, points to a symptom that deserves focused attention, while leaving larger questions about the treatment’s role for future research.

Another depression study explores how care can be better prepared to work. An international clinical trial found that 12 weeks of physical activity before cognitive behavioral therapy (CBT) improved participants’ fitness and was followed by gains in memory and learning during psychotherapy. Researchers linked the results to changes in IGF-1, a hormone involved in protecting and forming neurons. Exercise is not a replacement for therapy; the study suggests that combining interventions in sequence may help the brain engage with it.

Personalization also matters when a medication’s risks vary. Mayo Clinic researchers examined 70 BRCA2 gene variants that partially disrupt the gene’s function. People with these variants were estimated to have a 20% to 25% lifetime breast cancer risk, compared with 50% to 70% for people with more common harmful BRCA2 variants. Published in Nature Communications, the research could help care teams distinguish among risk levels and tailor conversations and care accordingly. A genetic finding need not mean every person faces the same future.

Small shifts, meaningful possibilities

The Lingnan University pain experiment began with a simple object: a cream participants believed might relieve pain, though it had no active ingredient. Among 187 healthy adults in two controlled experiments using a cold pressor test, researchers found that feeling ownership of the cream may help increase pain tolerance. The result, published in The Journal of Pain, doesn’t establish a treatment for chronic pain. It does invite further study of how expectation and a sense of control might complement other forms of pain care.

For adults seeking obesity treatment, researchers at the University of Pennsylvania’s Perelman School of Medicine reported that semaglutide was associated with greater improvement than placebo on several measures of disordered eating, eating-disorder symptoms and body-image concerns. The study appeared in the International Journal of Eating Disorders, with findings presented at ObesityWeek 2026 in Washington, D.C. The team’s work adds an important dimension to discussions of GLP-1 medicines: treatment outcomes can include people’s relationship with food and their bodies, not just weight.

And for people with Down syndrome, a phase 2 trial at the Linda Crnic Institute for Down Syndrome, part of the University of Colorado Anschutz, tested tofacitinib, a drug that blocks certain immune signals. Researchers reported reduced underlying inflammation and an association with improvements in inflammatory skin conditions. Published in Cell Reports Medicine, the work also opens questions about brain health and Alzheimer’s disease—but those are avenues for research, not established benefits of the treatment.

Better systems, not just new medicines

Care improves when the path to treatment is workable. At the University of Hong Kong, a long-term population study of people with treatment-resistant schizophrenia provides the first large-scale evidence from a Chinese population to support reviewing Hong Kong’s monthly blood-monitoring requirements for clozapine. The medication can be crucial for this severe form of schizophrenia, while repeated testing can burden patients, families and clinical services. The research, published in The British Journal of Psychiatry, offers evidence for weighing safety with timely access—not a reason to set monitoring aside.

The same drive to make care more practical reaches the dental clinic. An international team led by the University of Hong Kong developed DentalGEN, an AI framework designed to automate dental crown restoration. Published in npj Digital Medicine, the work brings together researchers from institutions including ShanghaiTech University, Shanghai Jiao Tong University, Wuhan University, HKUST and Texas A&M University. It points toward more capable digital dental manufacturing, while clinical verification and implementation will determine how the technology serves patients in practice.

The throughline is not that one breakthrough will solve health care. It is that useful progress can come from noticing what standard measures miss: pleasure, cognition, pain tolerance, body image, genetic differences, monitoring burdens and the practical craft of restoring a tooth. As these studies move into further testing and real-world care, patients and clinicians alike stand to benefit from treatments that are not only more advanced, but better matched to everyday lives.

Useful progress can come from noticing what standard measures miss: pleasure, cognition, pain tolerance, body image, genetic differences, monitoring burdens and the practical craft of restoring a tooth.

Comments (0)

No comments yet. Be the first to share your thoughts.